AbbVie (ABBV)

The Vanguard High Dividend Yield ETF (VYM) and the iShares Core High Dividend ETF (HDV) both provide exposure to U.S. dividend equities, but their income profiles are built differently. For investors evaluating yield, the key distinction is how much diversification sits behind the income stream.

AbbVie's shareholders can sleep easy.

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

The most recent research report on the "Allergy Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

When choosing dividend ETFs, diversification is a top priority.

These two exchange-traded funds have soundly beaten the markets during recent downturns.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold.

These players are seeing exciting results in clinical trials.

The most recent research report on the "Chemical Peel Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, and

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

These stocks are built for the long haul. And they pay great dividends.

When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.

The healthcare sector outperformed the rest of the market over the past week.

This big pharma stock checks off a lot of boxes.

Looking past stocks because they trade at high trailing earnings multiples can be a costly mistake for investors.

One is a well-known pharmaceutical company; the other is the king of the medical device segment.

Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This mig...

All High Quality Names

How does a rising 3.4% dividend and a growing portfolio of drugs sound?

It's not the news that AbbVie needed, given the challenging year it is having.